549 related articles for article (PubMed ID: 33929717)
1. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
Updike WH; Pane O; Franks R; Saber F; Abdeen F; Balazy DD; Carris NW
Drugs; 2021 Jun; 81(8):881-893. PubMed ID: 33929717
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
3. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
[TBL] [Abstract][Full Text] [Related]
4. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
[TBL] [Abstract][Full Text] [Related]
5. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
Ryan DH; Lingvay I; Colhoun HM; Deanfield J; Emerson SS; Kahn SE; Kushner RF; Marso S; Plutzky J; Brown-Frandsen K; Gronning MOL; Hovingh GK; Holst AG; Ravn H; Lincoff AM
Am Heart J; 2020 Nov; 229():61-69. PubMed ID: 32916609
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
Amaro A; Sugimoto D; Wharton S
Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309
[TBL] [Abstract][Full Text] [Related]
7. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
Burcelin R; Gourdy P
Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
Madsbad S; Holst JJ
Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
[TBL] [Abstract][Full Text] [Related]
9. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.
Sodhi M; Rezaeianzadeh R; Kezouh A; Etminan M
JAMA; 2023 Nov; 330(18):1795-1797. PubMed ID: 37796527
[TBL] [Abstract][Full Text] [Related]
10. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
Seijas-Amigo J; Salgado-Barreira Á; Castelo-Dominguez R; Pérez-Álvarez MT; Ponce-Piñón B; Fernández-Silva M; Rodríguez-Barreiro M; Pereira-Pía M; Iglesias-Moreno JM; Gago-García M; Montáns-García R; Fernandez-Perez A; FragaGayoso D; Fernandez-Montenegro M; Riveiro-Barciela B; Rilla-Villar N; Cordero A; RodríguezMañero M; González-Juanatey JR
Prim Care Diabetes; 2023 Aug; 17(4):366-372. PubMed ID: 37230813
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
Torekov SS
Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
[No Abstract] [Full Text] [Related]
12. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes.
Ng E; Shaw JE; Wood A; Maple-Brown LJ; Hare MJ
Aust J Gen Pract; 2022 Jul; 51(7):513-518. PubMed ID: 35773162
[TBL] [Abstract][Full Text] [Related]
13. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
14. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716
[TBL] [Abstract][Full Text] [Related]
15. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
[TBL] [Abstract][Full Text] [Related]
18. Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.
Powell J; Taylor J
Clin Ther; 2024 Mar; 46(3):289-292. PubMed ID: 38310052
[TBL] [Abstract][Full Text] [Related]
19. Practical guidance for use of oral semaglutide in primary care: a narrative review.
Morales J; Shubrook JH; Skolnik N
Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]